Keros Therapeutics, Inc.(KROS)

$11.63—Stale · unknown old

Keros Therapeutics, Inc.(KROS)

NASDAQ • Last print unknown ago

$11.63—Stale · unknown old

KROS(KROS)

KROS

Next report

Nov 4 2026in 41 days

EPS estimate

($0.96)

Revenue estimate

$15M

EPS beats

7 of last 12

Each report against the estimate that stood when it landed.

Nov 6 2023Aug 3 2026

Reported	EPS est	EPS actual	Surprise	Revenue est	Revenue actual	Surprise
Aug 3 2026	($1.34)	($1.45)	-8.2%	$807143	—	—
May 14 2026	($0.92)	($1.21)	-31.5%	$2M	$367000	-81.0%
Mar 4 2026	($0.49)	($0.86)	-75.5%	$4M	$385000	-89.5%
Nov 5 2025	($1.11)	($0.18)	+83.8%	$4M	$14M	+289.4%
Aug 6 2025	($1.14)	($0.76)	+33.3%	$3M	$18M	+465.9%
May 6 2025	($0.01)	$3.62	+36300.0%	$57M	$211M	+272.9%
Feb 26 2025	($1.36)	($1.14)	+16.2%	$22M	$3M	-86.3%
Nov 6 2024	($1.26)	($1.41)	-11.9%	$2M	$388000	-83.2%
Aug 7 2024	($1.23)	($1.25)	-1.6%	—	$37000	—
May 8 2024	($1.31)	($1.21)	+7.6%	—	$83000	—
Feb 28 2024	($1.38)	($1.34)	+2.9%	—	$143000	—
Nov 6 2023	($1.34)	($1.33)	+0.7%	—	$8000	—

Forward Growth Estimates (YoY)

FY2027

Rev-11.80%

EPS—

FY2028

Rev+225.61%

EPS—

FY2029

Rev+68.11%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$16M	$14M	$45M	$75M	$127M
Low	$1M	$9M	$45M	$7M	$11M
High	$23M	$18M	$45M	$102M	$173M
EBITDA Avg	$-207M	$-233M	$-144M	$-1.44B	$-43M
Low	$-233M	$-327M	$-340M	$-2.12B	$-71M
High	$-182M	$-139M	$-73M	$345M	$29M
EBIT Avg	$-209M	$-236M	$-149M	$-1.45B	$-59M
Low	$-235M	$-330M	$-345M	$-2.13B	$-86M
High	$-184M	$-142M	$-78M	$336M	$14M
Net Income Avg	$-209M	$-236M	$-149M	$-1.45B	$-59M
Low	$-235M	$-330M	$-345M	$-2.13B	$-86M
High	$-184M	$-142M	$-78M	$265M	$11M
EPS Avg	$-5.54	$-6.24	$-4.66	$-38.39	$-1.55
Low	$-6.20	$-8.71	$-9.12	$-56.16	$-2.26
High	$-4.85	$-3.75	$-2.07	$7.01	$0.28
Analysts (Rev / EPS)	5 / 5	5 / 5	6 / 6	4 / 3	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$15M	$478,571	$433,333	$433,333	$433,333	$433,333	—	—
Low	$384,200	$23,522	$21,298	$21,298	$21,298	$21,298	—	—
High	$22M	$683,832	$619,191	$619,191	$619,191	$619,191	—	—
EBITDA Avg	$-18M	$-38M	$-44M	$-32M	$-34M	$-35M	—	—
Low	$-29M	$-43M	$-68M	$-50M	$-53M	$-55M	—	—
High	$-12M	$-33M	$14M	$10M	$11M	$11M	—	—
EBIT Avg	$-19M	$-38M	$-44M	$-33M	$-35M	$-36M	—	—
Low	$-30M	$-44M	$-69M	$-51M	$-54M	$-56M	—	—
High	$-13M	$-33M	$13M	$10M	$10M	$11M	—	—
Net Income Avg	$-19M	$-38M	$-44M	$-33M	$-35M	$-36M	$-44M	$-45M
Low	$-30M	$-44M	$-69M	$-51M	$-54M	$-56M	$-69M	$-70M
High	$-13M	$-33M	$10M	$8M	$8M	$8M	$10M	$11M
EPS Avg	$-0.94	$-1.93	$-2.23	$-1.65	$-1.75	$-1.81	$-2.23	$-2.26
Low	$-1.50	$-2.21	$-3.47	$-2.57	$-2.73	$-2.82	$-3.47	$-3.52
High	$-0.64	$-1.67	$0.53	$0.39	$0.41	$0.43	$0.53	$0.53
Analysts (Rev / EPS)	4 / 3	4 / 4	2 / 1	2 / 1	2 / 1	2 / 1	— / 2	— / 2

No earnings transcripts available for KROS

Transcripts may not be available for all companies

Explore More

Filter and sort all 500 stocks

Continuous multi-factor scoring & catalyst forensics

Today's biggest gainers and losers